

ASX ANNOUNCEMENT

4 December 2025

Oversubscribed Placement Raising \$925,000

Key Highlights

- Placement completed to new and existing strategic, sophisticated investors on the same terms as the recent rights issue.
- Placement of shares at \$0.022 (2.2 cents) a discount of 8.3% to the closing price on 1 December 2025 and a discount of 11.9% to the 30-day VWAP, raising approximately \$925,000 before costs. The Placement also includes 1 attaching listed option for every 2 shares subscribed.
- General Meeting to be convened in January 2026 to seek approval for directors Tony Toohey and James Barrie to participate.
- Funds raised to be deployed to ongoing development and commercialisation activities and general working capital.

HITIQ Limited (ASX: HIQ) (**HITIQ** or the **Company**) is pleased to announce it has completed an oversubscribed placement to new and existing sophisticated investors, raising \$925,000 before costs through the issue of 42,045,455 ordinary shares (**Placement Shares**) at an issue price of \$0.022 per Placement Share (**Placement**). The Placement was scaled back to \$925,000 to fit within the Company's ASX Listing Rule 7.1 capacity.

This represents a discount of 8.3% to the closing price on 1 December 2025 and a discount of 11.9% to the 30-day VWAP. Funds raised will be deployed to ongoing development and commercialisation activities and general working capital.

HITIQ's Non-Executive Chairman, Earl Eddings, said:

"Subsequent to the rights issue completed earlier this year, we have remained in dialogue with a number of investors who had expressed interest to subscribe for additional shares in the Company. With the commercialisation of our concussion management technology gaining significant momentum, as evidenced by recent announcements, the Board resolved to progress with this capital raise to position the Company with a solid capital base heading into 2026. We are delighted to be welcoming several new sophisticated investors to our register, and coupled with support from existing investors, further validates the compelling long-term attractiveness of HITIQ's strategy."

The terms of the Placement are consistent with the rights issue completed earlier in 2025 and include one attaching new listed option (exercisable at \$0.022 and expiring on 30 December 2028) for every two shares issued under the Placement (**Placement Options**).

Directors Tony Toohey and James Barrie have subscribed under the Placement (**Participating Directors**), with their participation to be subject to shareholder approval at a general meeting to be convened in January 2026, details of which will be separately announced.

The issue of the Placement Shares and Placement Options will be completed under the Company's ASX Listing rule 7.1 capacity and (other than the Participating Directors) are expected to be issued on or before 12 December 2025.

SP Corporate Advisory Pty Ltd acted as Lead Manager for the Placement.

This announcement was approved for release by the Board of HITIQ Limited.

To learn more about this announcement please visit the HITIQ Investor Hub by clicking on the link below.

<https://investors.hitiq.com/link/e95Z0e>



Join our community

Receive alerts for announcements, news and updates direct to your inbox and engage with the HITIQ team using the Q&A tool.
Scan the QR code and sign up to our investor hub.



About HITIQ

HITIQ Limited (ASX: HIQ) pioneers concussion management technology, delivering smart mouthguards and software for sports, clinical, and research applications globally. Its PROTEQT™ system enhances athlete safety across elite and community sports.

About PROTEQT™

The PROTEQT™ instrumented mouthguard delivers comprehensive concussion management through impact detection, risk assessment, and integrated support services. Co-developed with Shock Doctor and building on proven Nexus technology, PROTEQT™ extends elite-level athlete protection to community sports globally.